Page 9 - Linical Evolution News Today

The U.K. startup Automata Technologies has bagged $40 million in a funding round to expand its workforce and the geographic reach of its life sciences lab automation technology.

A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.

The French-U.S. company Novadiscovery has hailed a “watershed moment for clinical trial design” as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.

The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.

An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.

The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startup’s drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.

HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.

Glasgow diagnostics spinout Microplate Dx has closed a £2.5 million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid.

The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.

The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.